Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Curated Accruing

NCT01725165Phase 2CompletedLung

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Completed MD Anderson randomized phase 2 trial of local consolidative therapy versus maintenance or observation in oligometastatic NSCLC. ClinicalTrials.gov API v2 on 13 Nov 2026: COMPLETED, actual enrollment 85, start 2012-11-28, primary completion 2024-05-08. The Tang 2020 correlative paper analyzed 31 of 49 randomized patients for ctDNA; those counts are not pooled with the registry enrollment of 85.

M.D. Anderson Cancer Center

NCT04642469Phase 3CompletedLung

MERMAID-2: durvalumab versus placebo for MRD-positive stage II to III NSCLC after curative therapy

Phase 3 trial of adjuvant durvalumab versus placebo in patients with resected stage II to III non-small cell lung cancer who become MRD-positive during surveillance without RECIST recurrence. ClinicalTrials.gov lists the study as completed.

AstraZeneca